

<b>Reference:</b>	FOI.13851.24
<b>Subject:</b>	Patient diagnosis and medication
<b>Date of Request:</b>	19 February 2024

**Requested:**

1. How many patient's does the trust have with a recorded diagnosis of Dravet Syndrome (DS)
  - a. Of these, how many have been treated with Epidyolex (Canabidiol) in the last 6 months?
  - b. Of these, how many have been treated with Fintepla (Fenfluramine) in the last 6 months?
2. How many patient's does the trust have with a recorded diagnosis of Lennox-Gastaut Syndrome (LGS)
  - a. Of these, how many have been treated with Epidyolex (Canabidiol) in the last 6 months?
  - b. Of these, how many have been treated with Fintepla (Fenfluramine) in the last 6 months?

**Response:**

1. Hywel Dda University Health Board (UHB) is unable to provide you with the information requested, due to the low number of cases (10 and under), as there is a potential risk of identifying individuals if this was disclosed. Therefore, the UHB is withholding these details under Section 40(2) of the Freedom of Information Act 2000 (FoIA).

This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

2. Section 40 exemption applied, as above.